FreedomEDGE Infusion System Positioning For Oncology Market Entry Via FDA Pathway In 2025/2026

KORU Medical Systems, Inc. (KRMD) is charting its course toward regulatory approval, with plans to file a 510(k) application with the FDA targeting Q4 2025 or early Q1 2026 for its FreedomEDGE Syringe Infusion System. The submission will focus on enabling the device’s use alongside a commercialized oncology therapeutic, marking a significant step in expanding the company’s market presence within the oncology space.

Clinical Evidence Strengthens Market Case

Recent multicentre study findings presented at the ESID/EHA/SIOPE Focused Symposium (November 18-20, 2025, Vienna) provide compelling validation for the FreedomEDGE platform. The research, titled “Comparing Mechanical Pump and Manual Push for Short-Duration Subcutaneous Infusions: A Nursing Preference Survey Study,” involved nine hospitals across Denmark and directly compared the FreedomEDGE System against conventional manual push administration techniques in oncology and immunology settings.

The results paint an encouraging picture: nursing teams reported high satisfaction levels, patients expressed strong approval ratings, and the system achieved a remarkable 97% recommendation rate among clinical staff. These metrics underscore the device’s potential to streamline clinical workflows while preserving patient comfort—a dual objective that has historically proven challenging in infusion technology.

Market Maturation and Scale

The FreedomEDGE Infusion System arrives with substantial real-world credentials. The platform boasts over 15 years of clinical deployment history, with more than 45,000 patients having self-administered treatments and approximately 2 million infusions completed annually. This operational footprint spans across 30+ countries, demonstrating geographic diversification and cross-market acceptance.

The device is engineered to simplify large-volume subcutaneous drug delivery across a substantial range—supporting infusion volumes from 5 mL to 50 mL and beyond. This versatility addresses a critical gap in current infusion infrastructure, particularly for therapies requiring higher volumes than traditional needle-based delivery can efficiently accommodate.

Strategic Significance and Investment Outlook

Brent Rutland, Vice President of Global Medical and Clinical Affairs at KORU Medical, emphasized that the multicentre study validates the company’s innovation focus. He highlighted how the FreedomEDGE System delivers a scalable, hands-free mechanism that enhances operational efficiency without compromising on the patient experience—positioning the technology as a differentiated solution in an increasingly competitive subcutaneous infusion marketplace.

From a market perspective, KRMD’s stock has operated within a $4.32 to $4.57 trading band over the past twelve months. Recent session activity saw the stock close at $4.49, reflecting a 3.94% gain and suggesting investor interest in the company’s near-term regulatory trajectory and potential oncology market expansion.